BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 32100833)

  • 1. Clinical experience of pelvic radiotherapy or chemoradiotherapy for postoperative uterine cervical cancer using intensity-modulated radiation therapy.
    Yamamoto T; Umezawa R; Tokunaga H; Kubozono M; Kozumi M; Takahashi N; Matsushita H; Kadoya N; Ito K; Sato K; Tsuji K; Shimada M; Jingu K
    J Radiat Res; 2020 May; 61(3):470-478. PubMed ID: 32100833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.
    Yin YJ; Li HQ; Sheng XG; Du XL; Wang C; Lu CH; Pan CX
    Int J Gynecol Cancer; 2015 Jul; 25(6):1058-65. PubMed ID: 25647254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer.
    Contreras J; Srivastava A; Chundury A; Schwarz JK; Markovina S; Thaker PH; Massad LS; Mutch DG; Powell MA; Grigsby PW; Lin AJ
    Int J Gynecol Cancer; 2020 Aug; 30(8):1157-1161. PubMed ID: 32527770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-operative small pelvic intensity-modulated radiation therapy for early-stage cervical cancer with intermediate-risk factors: efficacy and toxicity.
    Zhang G; He F; Miao L; Wu H; Zhang Y; Fu C
    Jpn J Clin Oncol; 2021 May; 51(6):905-910. PubMed ID: 33822980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes.
    Liang JA; Chen SW; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY
    Int J Gynecol Cancer; 2014 Jun; 24(5):901-7. PubMed ID: 23975081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-field intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy for postoperative cervical cancer with common iliac or para-aortic lymph node metastases: a retrospective review in a single institution.
    Zhang G; Fu C; Zhang Y; Wang J; Qiao N; Yang Q; Cheng Y
    Int J Gynecol Cancer; 2012 Sep; 22(7):1220-5. PubMed ID: 22854654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative pelvic intensity-modulated radiation therapy reduced the incidence of late gastrointestinal complications for uterine cervical cancer patients.
    Tsuchida K; Murakami N; Kato T; Okuma K; Okamoto H; Kashihara T; Takahashi K; Inaba K; Igaki H; Nakayama Y; Nakano T; Itami J
    J Radiat Res; 2019 Oct; 60(5):650-657. PubMed ID: 31251358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
    BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled study of single-agent cisplatin and radiotherapy versus docetaxel/cisplatin and radiotherapy in high-risk early-stage cervical cancer after radical surgery.
    Pu J; Qin SS; Ding JX; Zhang Y; Zhu WG; Yu CH; Li T; Tao GZ; Ji FZ; Zhou XL; Han JH; Ji YL; Sun JX
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):703-8. PubMed ID: 23328996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
    Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
    [No Abstract]   [Full Text] [Related]  

  • 12. Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer.
    Folkert MR; Shih KK; Abu-Rustum NR; Jewell E; Kollmeier MA; Makker V; Barakat RR; Alektiar KM
    Gynecol Oncol; 2013 Feb; 128(2):288-93. PubMed ID: 23159818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome and prognostic factors in cervical cancer patients treated with surgery and concurrent chemoradiotherapy: a retrospective study.
    Liu YM; Ni LQ; Wang SS; Lv QL; Chen WJ; Ying SP
    World J Surg Oncol; 2018 Jan; 16(1):18. PubMed ID: 29378625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
    Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
    Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of semiextended field intensity-modulated radiation therapy and concurrent cisplatin in locally advanced cervical cancer patients: An observational study of 10-year experience.
    Lee J; Lin JB; Sun FJ; Chen YJ; Chang CL; Jan YT; Wu MH
    Medicine (Baltimore); 2017 Mar; 96(10):e6158. PubMed ID: 28272204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of radical doses of pelvic radiotherapy for primary tumor treatment in patients with newly diagnosed organ metastatic cervical cancer.
    Yin Z; Lou H; Tang H; Ni J; Zhou Q; Chen M
    Radiat Oncol; 2019 May; 14(1):82. PubMed ID: 31109371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of concurrent weekly carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy as an adjuvant treatment for early-stage cervical cancer patients with positive pelvic lymph nodes.
    Mabuchi S; Takahashi R; Isohashi F; Yokoi T; Ito K; Tsutui T; Ogata T; Yoshioka Y; Ogawa K; Kimura T
    Int J Gynecol Cancer; 2013 Sep; 23(7):1279-86. PubMed ID: 23835505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity modulated radiation therapy boost in locally-advanced cervical cancer in the absence of brachytherapy.
    Lazzari R; Riva G; Augugliaro M; Vavassori A; Dicuonzo S; Cattani F; Comi S; Colombo N; Jereczek-Fossa BA
    Int J Gynecol Cancer; 2020 May; 30(5):607-612. PubMed ID: 32188626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensity modulated radiation therapy (IMRT) for sinonasal tumors: a single center long-term clinical analysis.
    Askoxylakis V; Hegenbarth P; Timke C; Saleh-Ebrahimi L; Debus J; Röder F; Huber PE
    Radiat Oncol; 2016 Feb; 11():17. PubMed ID: 26847089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic analysis of stage Ⅰb2 andⅡa2 cervical squamous cancer without high risk factors treated with neo-adjuvant chemotherapy and radical hysterectomy].
    Li PP; Li B; Wang YT; Liu SH; Zhang YN; Zhang R; Bai P; Li XG; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2018 Apr; 53(4):248-256. PubMed ID: 29747270
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.